5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the inve...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | BLAYO Anne-laure AMALRIC Camille SCHANN Stephan MAYER Stanislas FER Mickaël MANTEAU Baptiste |
| description | The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.
La presente invención se relaciona con nuevos derivados de 5-azaindazol de la fórmula (I), como se describe y define en la presente, y sus sales, solvatos y profármacos farmacéuticamente aceptables, así como composiciones farmacéuticas que comprenden tales compuestos. Se ha descubierto que los derivados de 5-azaindazol de acuerdo con la invención son antagonistas del receptor de adenosina duales A2A/A2B altamente eficaces y, por lo tanto, pueden usarse como agentes terapéuticos, particularmente en el tratamiento o prevención de enfermedades o trastornos hiperproliferativos o infecciosos. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_MX2021003508A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>MX2021003508A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_MX2021003508A3</originalsourceid><addsrcrecordid>eNrjZLA21XWMcvT0c3GM8vdxVXBxDfIMcwzxDHMNVnAEIhdXP_9gTz9XhSBXZ9eAEP8gBUe_EEd3fz_P4JBgHgbWtMSc4lReKM3NoOTmGuLsoZtakB-fWlyQmJyal1oS7xthZGBkaGBgbGpg4WhMlCIAO_cp6Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS</title><source>esp@cenet</source><creator>BLAYO Anne-laure ; AMALRIC Camille ; SCHANN Stephan ; MAYER Stanislas ; FER Mickaël ; MANTEAU Baptiste</creator><creatorcontrib>BLAYO Anne-laure ; AMALRIC Camille ; SCHANN Stephan ; MAYER Stanislas ; FER Mickaël ; MANTEAU Baptiste</creatorcontrib><description>The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.
La presente invención se relaciona con nuevos derivados de 5-azaindazol de la fórmula (I), como se describe y define en la presente, y sus sales, solvatos y profármacos farmacéuticamente aceptables, así como composiciones farmacéuticas que comprenden tales compuestos. Se ha descubierto que los derivados de 5-azaindazol de acuerdo con la invención son antagonistas del receptor de adenosina duales A2A/A2B altamente eficaces y, por lo tanto, pueden usarse como agentes terapéuticos, particularmente en el tratamiento o prevención de enfermedades o trastornos hiperproliferativos o infecciosos.</description><language>eng ; spa</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210527&DB=EPODOC&CC=MX&NR=2021003508A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210527&DB=EPODOC&CC=MX&NR=2021003508A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BLAYO Anne-laure</creatorcontrib><creatorcontrib>AMALRIC Camille</creatorcontrib><creatorcontrib>SCHANN Stephan</creatorcontrib><creatorcontrib>MAYER Stanislas</creatorcontrib><creatorcontrib>FER Mickaël</creatorcontrib><creatorcontrib>MANTEAU Baptiste</creatorcontrib><title>5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS</title><description>The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.
La presente invención se relaciona con nuevos derivados de 5-azaindazol de la fórmula (I), como se describe y define en la presente, y sus sales, solvatos y profármacos farmacéuticamente aceptables, así como composiciones farmacéuticas que comprenden tales compuestos. Se ha descubierto que los derivados de 5-azaindazol de acuerdo con la invención son antagonistas del receptor de adenosina duales A2A/A2B altamente eficaces y, por lo tanto, pueden usarse como agentes terapéuticos, particularmente en el tratamiento o prevención de enfermedades o trastornos hiperproliferativos o infecciosos.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLA21XWMcvT0c3GM8vdxVXBxDfIMcwzxDHMNVnAEIhdXP_9gTz9XhSBXZ9eAEP8gBUe_EEd3fz_P4JBgHgbWtMSc4lReKM3NoOTmGuLsoZtakB-fWlyQmJyal1oS7xthZGBkaGBgbGpg4WhMlCIAO_cp6Q</recordid><startdate>20210527</startdate><enddate>20210527</enddate><creator>BLAYO Anne-laure</creator><creator>AMALRIC Camille</creator><creator>SCHANN Stephan</creator><creator>MAYER Stanislas</creator><creator>FER Mickaël</creator><creator>MANTEAU Baptiste</creator><scope>EVB</scope></search><sort><creationdate>20210527</creationdate><title>5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS</title><author>BLAYO Anne-laure ; AMALRIC Camille ; SCHANN Stephan ; MAYER Stanislas ; FER Mickaël ; MANTEAU Baptiste</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_MX2021003508A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; spa</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>BLAYO Anne-laure</creatorcontrib><creatorcontrib>AMALRIC Camille</creatorcontrib><creatorcontrib>SCHANN Stephan</creatorcontrib><creatorcontrib>MAYER Stanislas</creatorcontrib><creatorcontrib>FER Mickaël</creatorcontrib><creatorcontrib>MANTEAU Baptiste</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BLAYO Anne-laure</au><au>AMALRIC Camille</au><au>SCHANN Stephan</au><au>MAYER Stanislas</au><au>FER Mickaël</au><au>MANTEAU Baptiste</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS</title><date>2021-05-27</date><risdate>2021</risdate><abstract>The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.
La presente invención se relaciona con nuevos derivados de 5-azaindazol de la fórmula (I), como se describe y define en la presente, y sus sales, solvatos y profármacos farmacéuticamente aceptables, así como composiciones farmacéuticas que comprenden tales compuestos. Se ha descubierto que los derivados de 5-azaindazol de acuerdo con la invención son antagonistas del receptor de adenosina duales A2A/A2B altamente eficaces y, por lo tanto, pueden usarse como agentes terapéuticos, particularmente en el tratamiento o prevención de enfermedades o trastornos hiperproliferativos o infecciosos.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; spa |
| recordid | cdi_epo_espacenet_MX2021003508A |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T01%3A27%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BLAYO%20Anne-laure&rft.date=2021-05-27&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EMX2021003508A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |